½ÃÀ庸°í¼­
»óǰÄÚµå
1378595

¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, ÀûÀÀÁõº°, ¿ëµµº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°

Spinal Cord Injury Therapeutics Market, By Drug Type, By Indication, By Application, By Route of Administration, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 74¾ï ´Þ·¯·Î ÃßÁ¤¡¤¿¹ÃøµÇ¸ç, ¿¹Ãø±â°£ Áß(2023-2030³â) CAGRÀº 5.4%·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁس⵵ 2022³â 2023³â ½ÃÀå ±Ô¸ð 74¾ï ´Þ·¯
°ú°Å µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030³â
¿¹Ãø ±â°£ÀÇ CAGR 5.40% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 107¾ï ´Þ·¯
±×¸² 1. ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²(%), ÀûÀÀÁõº°, 2023³â
Spinal Cord Injury Therapeutics Market-IMG1

ô¼ö¼Õ»óÀ̶õ 31½ÖÀÇ Ã´¼ö½Å°æ¿¡ »ý±â´Â »óó·Î, ô¼ö½Å°æÀº Á¤½ÅÀ¸·ÎºÎÅÍÀÇ ½Å°æ½ÅÈ£¸¦ ½ÅüÀÇ ´Ù¾çÇÑ ºÎÀ§¿¡ Àü´ÞÇÏ´Â µ¿½Ã¿¡ ÆÈ°ú ´Ù¸®ÀÇ ¹ßÀ°À» Á¦¾îÇϰí ÀÖ½À´Ï´Ù. ô¼öÀÇ »óóÀÇ ±âº» ¿øÀÎÀº »óÇØ, ô¼ö¿¡ Ç÷¾× °ø±ÞÀÇ ¼Õ½Ç, ¾Ï°ú ¿À¿°À¸·Î ÀÎÇÑ Ã´¼öÀÇ ¾Ð¹Ú µîÀÔ´Ï´Ù. ô¼öÀÇ »óó´Â ¿¹¸¦ µé¾î X ºö, ¾îÆ®·¢Æ¼ºê ¸®¹öºê·¹ÀÌ¼Ç ·¹ÄÚµå(MRI), ÇDZԾî Åä¸ð±×·¡ÇÇ(CT) µî ´Ù¾çÇÑ ¹æ¹ýÀÇ µµ¿òÀ¸·Î ÆÇ´ÜÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¦¾à »ê¾÷ÀÇ ÁÖ¿ä ±â¾÷Àº ô¼ö ¼Õ»óÀÇ Ä¡·á¿Í °ü·ÃµÈ ¾à¹°ÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Ã·´Ü Á¦Ç°ÀÌ ½ÃÀå¿¡ µµÀÔµÊÀ¸·Î½á ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ

Á¦¾à ¾÷°èÀÇ ÁÖ¿ä ±â¾÷Àº ô¼ö ¼Õ»ó Ä¡·á¸¦ À§ÇÑ ½Å¾à °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Ã·´Ü Á¦Ç°ÀÌ ½ÃÀå¿¡ µµÀÔµÊÀ¸·Î½á ¿¹Ãø ±â°£¿¡ °ÉÃÄ ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 6¿ù ¿ÏÀü ÅëÇÕÇü Çʼö ÀǾàǰ ±â¾÷ÀÎ Amneal Pharmaceuticals, Inc. ¹ÙŬ·ÎÆæ °æ±¸ °ú¸³(5, 10, 20mg) Àü¹® Á¦Ç°ÀÎ LYVISPAHÀÇ »ó¾÷Àû Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2023-2030³â) ½ÃÀå ±Ô¸ð ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR)À» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ¼ºÀå ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾ÈÀÇ Çà·Ä¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • º» ¿¬±¸ÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷Àº Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc., Kringle Pharma, Inc, NervGen, Rising Pharmaceuticals, ScieGen Pharmaceuticals, MSN Laboratories Private Limited, Lannett Co Inc.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ô¼ö ¼Õ»ó Ä¡·áÁ¦ ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü¿©ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

  • Á¶»çÀÇ ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ÃÖ±Ù Å×½ºÆ® ¹ß»ç
  • ¿ªÇÐ
  • ÇÕº´, Àμö ¹× Çù¾÷
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÁÖ¿ä ¹ßÀü
  • PEST ºÐ¼®

Á¦4Àå ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : COVID-19 ¿µÇ⠺м®

  • °æÁ¦Àû ¿µÇâ
  • ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • ¼ö¿ä ¹× °ø±Þ¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°(2018-2030³â)

  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • ±ÙÀ° ÀÌ¿ÏÁ¦ ¹× Ç× °æ·ÃÁ¦
  • ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAID'S)
  • Ç׿ì¿ïÁ¦
  • Ç×°æ·ÃÁ¦
  • ±âŸ

Á¦6Àå ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : ÀûÀÀÁõº°(2018-2030³â)

  • ¿ÏÀü ô¼ö ¼Õ»ó
  • ºÒ¿ÏÀü ô¼ö ¼Õ»ó

Á¦7Àå ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°(2018-2030³â)

  • ÀÚÀ²½Å°æ½ÇÁ¶Áõ(AD)
  • °æ·Ã°ú ¿°Áõ
  • ÅëÁõ °ü¸®
  • ¿ì¿ï

Á¦8Àå ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°(2018-2030³â)

  • °æ±¸
  • Á¤¸Æ³»

Á¦9Àå ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº°(2018-2030³â)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦10Àå ¼¼°è ô¼ö ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°(2018-2030³â)

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie Inc
    • Pfizer Inc.
    • Reddy's Laboratories Ltd
    • Zydus Cadila
    • ReNetX Bio, Inc
    • InVivo Therapeutics Holdings
    • Lineage Cell Therapeutics, Inc
    • Kringle Pharma, Inc.
    • Acorda Therapeutics, Inc.
    • Bioaxone Biosciences, Inc
    • RespireRx Pharmaceuticals Inc.
    • NervGen
    • Rising Pharmaceuticals, Inc
    • ScieGen Pharmaceuticals, Inc
    • MSN Laboratories Private Limited
    • Lannett Co Inc.
    • Other Prominent Players

Á¦12Àå ¼½¼Ç

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
JHS 23.11.21

The Global Spinal Cord Injury Therapeutics Market is estimated to be valued at US$ 7.4 billion in 2023 and is expected to exhibit a CAGR of 5.4% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 7.4 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5.40% 2030 Value Projection: US$ 10.7 Bn
Figure 1. Global Spinal Cord Injury Therapeutics Market Share (%), By Indication, 2023
Spinal Cord Injury Therapeutics Market - IMG1

Spinal cord wounds are the wounds caused to the 31 sets of spinal nerves, which convey nerve signals from the mind to different parts of the body and likewise control the arm and leg developments. The fundamental driver of spinal cord wounds incorporate injury, loss of blood supply to the spinal cord, and pressure in the spinal cord because of cancer or contamination. Spinal cord wounds can be determined to have the assistance of different methods, for example, X-beam, attractive reverberation record (MRI), and figured tomography (CT). Key players in the pharmaceutical industry are focusing on the development of drugs associated with the treatment of spinal cord injuries. Thus, the introduction of such advanced products in the market is expected to drive the growth of the global spinal cord injury therapeutics market over the forecast period.

Market Dynamics

The key players in the pharmaceutical industry are focusing on the development of new drugs for spinal cord injury treatment. Thus, the introduction of such advanced products in the market is expected to drive growth of the global spinal cord injury therapeutics market over the forecast period. For instance, in June 2022, Amneal Pharmaceuticals, Inc., a fully integrated essential medicines company, announced the commercial launch of LYVISPAH, a baclofen oral granules (5, 10 and 20 mg) specialty product approved by the U.S. Food and Drug Administration (FDA) for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders.

Key features of the study:

  • This report provides an in-depth analysis of the global spinal cord injury therapeutics market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global spinal cord injury therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc, Pfizer Inc., Reddy's Laboratories Ltd, Zydus Cadila, ReNetX Bio, Inc, InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc, Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc, RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc, ScieGen Pharmaceuticals, Inc, MSN Laboratories Private Limited, and Lannett Co Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global spinal cord injury therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal cord injury therapeutics market

Global Spinal Cord Injury Therapeutics Market Detailed Segmentation:

  • By Drug Type:
    • Corticosteroids
    • Muscle Relaxants and Anti-spastic drugs
    • Non-steroidal Anti-inflammatory drugs (NSAID'S)
    • Anti-depressants
    • Anticonvulsants
    • Others
  • By Indication:
    • Complete Spinal Cord Injury
    • Incomplete Spinal Cord Injury
  • By Application:
    • Autonomic Dysreflexia (AD)
    • Spasticity and Inflammation
    • Pain Management
    • Depression
  • By Route of Administration:
    • Oral
    • Intravenous
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie Inc
    • Pfizer Inc.
    • Reddy's Laboratories Ltd
    • Zydus Cadila
    • ReNetX Bio, Inc
    • InVivo Therapeutics Holdings
    • Lineage Cell Therapeutics, Inc
    • Kringle Pharma, Inc.
    • Acorda Therapeutics, Inc.
    • Bioaxone Biosciences, Inc
    • RespireRx Pharmaceuticals Inc.
    • NervGen
    • Rising Pharmaceuticals, Inc
    • ScieGen Pharmaceuticals, Inc
    • MSN Laboratories Private Limited
    • Lannett Co Inc.
    • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By Application
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Test Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Spinal Cord Injury Therapeutics Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Spinal Cord Injury Therapeutics Market, By Drug Type, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Muscle Relaxants and Anti-spastic Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Non-steroidal Anti-inflammatory Drugs (NSAID'S)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Anti-depressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Anticonvulsants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

6. Global Spinal Cord Injury Therapeutics Market, By Indication, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Complete Spinal Cord Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Incomplete Spinal Cord Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

7. Global Spinal Cord Injury Therapeutics Market, By Application, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Autonomic Dysreflexia (AD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Spasticity and Inflammation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Pain Management
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Depression
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

8. Global Spinal Cord Injury Therapeutics Market, By Route of Administration, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

9. Global Spinal Cord Injury Therapeutics Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

10. Global Spinal Cord Injury Therapeutics Market, By Region, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 - 2030, (US$ Bn
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 - 2030, (US$ Bn
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 - 2030, (US$ Bn
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 - 2030, (US$ Bn
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 - 2030, (US$ Bn
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 - 2030, (US$ Bn
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 - 2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

11. Competitive Landscape

  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • AbbVie Inc
    • Pfizer Inc.
    • Reddy's Laboratories Ltd
    • Zydus Cadila
    • ReNetX Bio, Inc
    • InVivo Therapeutics Holdings
    • Lineage Cell Therapeutics, Inc
    • Kringle Pharma, Inc.
    • Acorda Therapeutics, Inc.
    • Bioaxone Biosciences, Inc
    • RespireRx Pharmaceuticals Inc.
    • NervGen
    • Rising Pharmaceuticals, Inc
    • ScieGen Pharmaceuticals, Inc
    • MSN Laboratories Private Limited
    • Lannett Co Inc.
    • Other Prominent Players

12. Section

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦